India · Delayed Price · Currency is INR Pfizer Statistics
Total Valuation
Pfizer has a market cap or net worth of INR 220.68 billion. The enterprise value is 190.50 billion.
| Market Cap | 220.68B |
| Enterprise Value | 190.50B |
Important Dates
The last earnings date was Tuesday, July 28, 2026.
| Earnings Date | Jul 28, 2026 |
| Ex-Dividend Date | Jul 17, 2026 |
Share Statistics
| Current Share Class | 45.75M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 17.92% |
| Float | 15.10M |
Valuation Ratios
The trailing PE ratio is 30.02 and the forward PE ratio is 25.62.
| PE Ratio | 30.02 |
| Forward PE | 25.62 |
| PS Ratio | 8.59 |
| PB Ratio | 5.25 |
| P/TBV Ratio | 6.03 |
| P/FCF Ratio | 23.42 |
| P/OCF Ratio | 22.81 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.27, with an EV/FCF ratio of 20.22.
| EV / Earnings | 25.91 |
| EV / Sales | 7.41 |
| EV / EBITDA | 20.27 |
| EV / EBIT | 21.53 |
| EV / FCF | 20.22 |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.07 |
| Debt / FCF | 0.07 |
| Interest Coverage | 115.04 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 55.29% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 20.66M |
| Profits Per Employee | 5.91M |
| Employee Count | 1,244 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Pfizer has paid 2.58 billion in taxes.
| Income Tax | 2.58B |
| Effective Tax Rate | 25.95% |
Stock Price Statistics
The stock price has decreased by -8.27% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -8.27% |
| 50-Day Moving Average | 4,581.22 |
| 200-Day Moving Average | 4,837.07 |
| Relative Strength Index (RSI) | 65.90 |
| Average Volume (20 Days) | 1,680 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pfizer had revenue of INR 25.70 billion and earned 7.35 billion in profits. Earnings per share was 160.70.
| Revenue | 25.70B |
| Gross Profit | 16.49B |
| Operating Income | 8.85B |
| Pretax Income | 9.93B |
| Net Income | 7.35B |
| EBITDA | 9.06B |
| EBIT | 8.85B |
| Earnings Per Share (EPS) | 160.70 |
Balance Sheet
The company has 30.88 billion in cash and 702.30 million in debt, with a net cash position of 30.18 billion.
| Cash & Cash Equivalents | 30.88B |
| Total Debt | 702.30M |
| Net Cash | 30.18B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 42.03B |
| Book Value Per Share | 918.71 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 9.68 billion and capital expenditures -252.30 million, giving a free cash flow of 9.42 billion.
| Operating Cash Flow | 9.68B |
| Capital Expenditures | -252.30M |
| Depreciation & Amortization | 216.55M |
| Net Borrowing | -381.70M |
| Free Cash Flow | 9.42B |
| FCF Per Share | n/a |
Margins
Gross margin is 64.19%, with operating and profit margins of 34.43% and 28.61%.
| Gross Margin | 64.19% |
| Operating Margin | 34.43% |
| Pretax Margin | 38.63% |
| Profit Margin | 28.61% |
| EBITDA Margin | 35.27% |
| EBIT Margin | 34.43% |
| FCF Margin | 37.40% |
Dividends & Yields
This stock pays an annual dividend of 75.00, which amounts to a dividend yield of 1.58%.
| Dividend Per Share | 75.00 |
| Dividend Yield | 1.58% |
| Dividend Growth (YoY) | -54.55% |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 1.58% |
| Earnings Yield | 3.33% |
| FCF Yield | 4.27% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Pfizer is 6,658.50, which is 31.28% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 6,658.50 |
| Price Target Difference | 31.28% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |